Indonesian In Vitro Diagnostics Company PRDL Officially Listed on the Indonesia Stock Exchange

July 9, 2026 The initial listing of PT Prodia Diagnostic Line Tbk (PRDL) shares on the Indonesia Stock Exchange is a strategic step in supporting the growth of the In Vitro Diagnostics (IVD) industry in Indonesia.

PT Prodia Diagnostic Line Tbk, part of the Prodia Group, officially listed its initial shares on the Indonesia Stock Exchange (IDX: PRDL) on July 9, 2026, marking a strategic step in strengthening the In Vitro Diagnostics (IVD) industry in Indonesia. 

As an entity entering the public market, PRDL is supported by solid business fundamentals, strong governance, and Prodia Group's experience and capabilities in building an integrated healthcare ecosystem. 

The in vitro diagnostics industry in Indonesia continues to grow in line with the increasing demand for healthcare services, facility expansion, and early disease detection programs. In line with this, PRDL has products with a Domestic Content Level (TKDN) above 40%, demonstrating its commitment to supporting the independence of the national medical device industry. 

As a shareholder, PT Prodia Widyahusada Tbk (PRDA) is proud to support PRDL's continued growth and contribution to the development of the healthcare diagnostic services ecosystem in Indonesia. 

More information about PRDL:
proline.co.id